atorvastatin has been researched along with Heart Diseases in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Qadir, H; Amir, E; Billia, F; Brezden-Masley, C; Chan, J; Connelly, KA; Hanneman, K; Houbois, C; Huang, F; Kei, T; Marwick, TH; Maze, D; Pezo, RC; Power, C; Prica, A; Runeckles, K; Saha, S; Shalmon, T; Thavendiranathan, P; Thorpe, KE; Wintersperger, BJ | 1 |
| Abramson, JS; Armand, P; Asnani, A; Barnes, JA; Brahmbhatt, P; Drobni, ZD; Friedman, RS; Gilman, HK; Han, Y; Heemelaar, JC; Ho, JS; Hochberg, EP; Hua, L; Jacobsen, ED; Jacobson, CA; Januzzi, JL; Jerosch-Herold, M; Kim, AI; Kwong, RY; Ky, B; Lacasce, AS; Landsburg, D; Mahmood, SS; Mousavi, N; Nasta, S; Neilan, TG; Neuberg, DS; Onoue, T; Quinaglia, T; Redd, RA; Sama, S; Scherrer-Crosbie, M; Smith, A; Soumerai, JD; Svoboda, J | 1 |
| Alenabi, A; Hallaj-Salahipour, M; Khoramjouy, M; Malekinejad, H; Malekinejad, M; Masoumi Verki, M | 1 |
| Cheung, K; McKillip, J; Powers, EM; Powers, JG | 1 |
| Choi, SY; Kim, CR; Kim, MH; Park, JS; Roh, MS; Serebruany, V | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Küçüker, A; Kunt, A; Odabaşi, D; Özcan, S; Sami Kunt, A | 2 |
| Chen, M; Li, H; Shen, X; Su, W; Wang, G; Zhao, S | 1 |
| Chen, ZC; Cheng, KL; Cheng, SY; Guo, YZ; Ou, MD; Wang, Q; Xue, JJ; Zeng, WJ; Zhang, YT | 1 |
| Abbassi, MM; Elkaffas, S; Elmarsafawi, AG; Elsawy, HM; Sabry, NA | 1 |
| Al-Khayatt, MS; Brull, DJ; Campbell, VL; O'Mahony, C | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK | 1 |
| Lopatin, IuM | 1 |
| Takagi, H; Umemoto, T | 1 |
| Beevers, DG; Lim, HS; Lip, GY; Nadar, S | 1 |
| Gross, B; Hättenschwiler, A; Schulthess, G; Widmer, Ch | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Candura, D; Chello, M; Covino, E; D'Ambrosio, A; Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Honey, K | 1 |
| Messerli, FH | 1 |
| Kulbertus, H | 1 |
| Braunwald, E | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
1 review(s) available for atorvastatin and Heart Diseases
| Article | Year |
|---|---|
Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Heart Diseases; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
9 trial(s) available for atorvastatin and Heart Diseases
| Article | Year |
|---|---|
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Biomarkers; Breast Neoplasms; Cardiotoxicity; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke Volume; Ventricular Function, Left | 2023 |
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Cardiovascular Agents; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Heart Failure; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2023 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Effects of perioperative statin treatment on postoperative atrial fibrillation and cardiac mortality in patients undergoing coronary artery bypass grafting: a propensity score analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Bypass; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Perioperative Care; Postoperative Complications; Propensity Score; Retrospective Studies | 2015 |
Efficacy of Different Perioperative Statin Regimens on Protection Against Post-Coronary Artery Bypass Grafting Major Adverse Cardiac and Cerebral Events.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cerebrovascular Disorders; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Creatine Kinase; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Perioperative Care; Prospective Studies; Quality of Life; Troponin I | 2016 |
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
Topics: Aged; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Cardiac Surgical Procedures; Cerebrovascular Disorders; Female; Heart Diseases; Heptanoic Acids; Humans; Length of Stay; Male; Middle Aged; Postoperative Complications; Pyrroles | 2006 |
Drug designed to raise HDL levels falls down.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Industry; Heart Diseases; Heptanoic Acids; Humans; Lipoproteins, HDL; Pyrroles; Quinolines | 2007 |
17 other study(ies) available for atorvastatin and Heart Diseases
| Article | Year |
|---|---|
Cardioprotective Effects of Atorvastatin Are Mediated Through PPARγ in Paraquat-Exposed Rats.
Topics: Animals; Antioxidants; Atorvastatin; Cardiotoxicity; Creatine Kinase, MB Form; Cyclooxygenase 2; Disease Models, Animal; Heart Diseases; Lipid Peroxidation; Male; Myocytes, Cardiac; Nitric Oxide; Oxidative Stress; Paraquat; Peroxidase; PPAR gamma; Rats, Wistar; Signal Transduction; Sulfhydryl Compounds | 2019 |
Effect of statin use on incidence of eczema and atopic dermatitis: A retrospective cohort study.
Topics: Adult; Age Factors; Atorvastatin; Dermatitis, Atopic; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Simvastatin; Young Adult | 2021 |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Angiotensin II; Animals; Atorvastatin; Collagen Type I; Collagen Type III; Fibrosis; Gene Expression Regulation; Gene Knockout Techniques; Heart Diseases; Injections, Subcutaneous; Male; Mice; Phosphorylation; Treatment Outcome | 2017 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Efficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: low-dose versus high-dose.
Topics: Atorvastatin; Coronary Artery Bypass; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postoperative Complications; Retrospective Studies | 2015 |
Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ).
Topics: Actins; Anilides; Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Down-Regulation; Fibrosis; Glycation End Products, Advanced; Heart Diseases; Heart Function Tests; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Ultrasonography | 2016 |
The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease.
Topics: Animals; Aorta; Apoptosis; Arterioles; Atorvastatin; Cell Proliferation; Heart Diseases; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inflammation; Lung; Macrophages; Male; Myocardial Ischemia; Neutrophils; Rats; Rats, Sprague-Dawley | 2016 |
Rhabdomyolysis with atorvastatin and fusidic acid.
Topics: Aged; Anti-Bacterial Agents; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Floxacillin; Fusidic Acid; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteomyelitis; Pyrroles; Rhabdomyolysis | 2008 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
["Gout tophi" and heart disease in the family].
Topics: Adult; Arcus Senilis; Atorvastatin; Cholesterol; Cholesterol, HDL; Diagnosis, Differential; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Heart Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Time Factors; Xanthomatosis | 2003 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing | 2005 |
Amlodipine/atorvastatin for preventing heart disease.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Drug Combinations; Heart Diseases; Heptanoic Acids; Humans; Pyrroles | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Reducing myocardial injury by minimizing imbalance between oxygen supply and demand.
Topics: Anesthesiology; Animals; Atorvastatin; Blood Pressure; Cardiovascular Agents; Coronary Disease; Dogs; Heart Diseases; Heart Rate; Heptanoic Acids; History, 20th Century; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Necrosis; Oxygen; Pyrroles | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |